The demo attained both its Principal endpoints, with semaglutide two.four mg demonstrating statistically major and top-quality enhancements in liver fibrosis without any worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH when compared with placebo.1I possess the ve